Safety and efficacy of early oral switch in Enterobacterales bacteremia: a systematic review and meta-analysis
- Author:
Rafael LEVANDOWSKI
1
;
Tae Yoon HWANG
;
Sangwoon BAE
;
Kyeong-Soo LEE
Author Information
- Publication Type:Original article
- From: Journal of Yeungnam Medical Science 2026;43(1):12-
- CountryRepublic of Korea
- Language:0
-
Abstract:
Background:Early oral switch (EOS) has been proposed as an alternative to prolonged intravenous (IV) therapy for Enterobacterales bacteremia; however, its safety and effectiveness have not been clearly established. This systematic review and meta-analysis evaluated whether EOS reduces treatment failure in uncomplicated Enterobacterales bacteremia and examined how the timing of switching affects outcomes.
Methods:We conducted a systematic review and random-effects meta-analysis of randomized controlled trials and observational studies that compared EOS with continued IV therapy in adults with uncomplicated Enterobacterales bacteremia. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. The primary outcome was treatment failure by ≤90 days. Prespecified analyses evaluated the timing of the switch.
Results:Across 10 studies that met the inclusion criteria, EOS was associated with lower treatment failure than continued IV therapy (RR, 0.72; 95% CI, 0.58–0.89; I²=26%). Switching within 4 days reduced the failure (RR, 0.58; 95% CI, 0.44–0.76; I²=0%), whereas switching after 4 days showed no clear advantage (RR, 0.87; 95% CI, 0.71–1.06; I²=0%). No evidence of small study effects was observed.
Conclusion:EOS was associated with a lower risk of treatment failure than prolonged IV therapy, with the greatest benefit observed when the switch occurred within 4 days. These findings should be interpreted with clinical caution given that most of the evidence is observational.
